Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why? -- Ignore unavailable to you. Want to Upgrade?

To: Mo Chips who wrote (401)	12/23/1997 3:22:00 PM
From: Konehead	Read Replies (1) \| Respond to of 763

D*mn, I got burned on this one too. Bye bye $12 K and merry christmas. I thought I had a bargain at $30. The company has projecting growth to slow to 40% or so. Anyone have a guess how the quarter will end up? A 17x multiple seems really low if Remedy is merely readjusting to a slowing growh rate (100%->40%). On the other hand, if it's a Clarify or Scopus scenario (flat revenues for several quarters, no earnings) then maybe I should get out. Any thoughts? Whaaa!

To: Mo Chips who wrote (401)	12/23/1997 3:30:00 PM
From: James Bowser	Respond to of 763

Down 35%? You'd think they said they would miss their revenues and earnings by a 1/3. The Goldman downgrade is due to concern about IBM's Tivoli division buying SWRT. How much revenue does Tivoli provide for RMDY? Anyone?